Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. human stem cell derived
Show results for
Products
Services

Companies

News
Articles
Videos

Refine by
Date

  • Older

Human Stem Cell Derived Articles & Analysis

10 news found

BIOtechNOW featured IVS’s participating BIO Innovation Zone

BIOtechNOW featured IVS’s participating BIO Innovation Zone

Ayla Annac, InvivoSciences: InvivoSciences (IVS) is a leading developer of proprietary, award-winning platform technologies that creates human 3D cell/tissue culture models and their automated phenotype analyzers for drug discovery and precision medicine development. ...

ByInvivoSciences, Inc. (IVS)


BIO Investor Forum Company Snapshot: InvivoSciences

BIO Investor Forum Company Snapshot: InvivoSciences

(IVS) is a leading developer of proprietary human 3D cell/tissue culture models for highly-predictive, multi-parameter phenotypic assays both in pharmacology safety & discovery screening and in personalized and regenerative medicine. ...

ByInvivoSciences, Inc. (IVS)


NIH/NIDDK Phase II SBIR Awarded Sept 2015

NIH/NIDDK Phase II SBIR Awarded Sept 2015

Human induced pluripotent stem cell-derived beta-cells for drug and toxicity ...

ByRegenerative Medical Solutions Inc. (RMS)


Celularity Reports First Quarter 2022 Financial Results and Provides Corporate Update

Celularity Reports First Quarter 2022 Financial Results and Provides Corporate Update

” First Quarter Clinical and Regulatory Updates CYNK-001 for the Treatment of AML and GBM: CYNK-001 is Celularity’s unmodified cryopreserved human placental hematopoietic stem cell-derived NK cell therapy candidate that is enriched with CD56+/CD3- NK cells and expanded from ...

ByCelularity Inc.


Celularity Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Celularity Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

” Clinical and Regulatory Updates CYNK-001 for the Treatment of AML and GBM: CYNK-001 is Celularity’s unmodified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy candidate that is enriched with CD56+/CD3- NK cells and expanded from ...

ByCelularity Inc.


Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML

Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML

(Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its non-genetically modified cryopreserved human placental hematopoietic stem ...

ByCelularity Inc.


AIVITA Biomedical’s Stem Cell-Derived Retina Transplant Restores Vision Loss in Preclinical Study

AIVITA Biomedical’s Stem Cell-Derived Retina Transplant Restores Vision Loss in Preclinical Study

– Oct. 29, 2021 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced the publication of the peer-reviewed manuscript, “Co-grafts of Human Stem Cell-Derived Retina Organoids and Retinal Pigment Epithelium for Retinal ...

ByAIVITA Biomedical, Inc.


StemBioSys participates in Biotech Showcase Digital during J.P. Morgan Week 2021

StemBioSys participates in Biotech Showcase Digital during J.P. Morgan Week 2021

StemBioSys, Inc., a privately held biomedical company that manufactures and develops innovative, advanced human stem cell technologies to improve the predictive power of pre-clinical drug safety screening, today announced its President and Chief Executive Officer Bob Hutchens will participate in Biotech Showcase Digital being held January ...

ByStemBioSys, Inc.


StemBioSys and Cartox Announce Publication of Research Demonstrating CELLvo™ Matrix Plus Significantly Enhances the Functionality of hiPSC Cardiomyocytes

StemBioSys and Cartox Announce Publication of Research Demonstrating CELLvo™ Matrix Plus Significantly Enhances the Functionality of hiPSC Cardiomyocytes

(Cartox) announced today the publication of research in Nature Scientific Reports demonstrating that CELLvo™ Matrix Plus, an extracellular matrix (ECM) technology derived from human perinatal stem cells, supports rapid functional and structural maturation of human induced pluripotent stem ...

ByStemBioSys, Inc.


ArunA Biomedical, Inc. in Athens, GA awarded more than $79,000 for Developmental Neurotox Assay Using Scalable Neurons and Astrocytes in High-Content Imaging

ArunA Biomedical will develop a rapid, scalable, human pluripotent stem cell-derived cell-based coculture assay system to address a critical gap where animal developmental neurotoxicity testing for a single compound can be financially prohibitive (in excess of $1 million) and time consuming (up to 1.5 yrs). ArunA ...

ByUS EPA - Environmental Protection Agency

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT